Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ming-Lung Yu

Showing results (501-510 of 527) with videos related to

Pageof 53
Sort By:
Scientific Reports|December 7, 2021
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in TaiwanChung-Feng Huang, Hsing-Tao Kuo, Te-Sheng Chang, et al.
Journal of Viral Hepatitis|September 13, 2025
Impact of Concurrent Steatotic Liver Disease and Chronic Hepatitis B on Treatment Response to Nucleos(t)ide AnalogsAngela Chau, Jie Li, Dae Won Jun, et al.
Hepatology International|January 21, 2024
An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from TaiwanMing-Lung Yu, Chi-Ming Tai, Lein-Ray Mo, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 6, 2022
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in TaiwanChing-Chu Lo, Chung-Feng Huang, Pin-Nan Cheng, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 5, 2021
Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision MedicineJiyoon Park, An K Le, Tai-Chung Tseng, et al.
JHEP Reports : Innovation in Hepatology|July 18, 2024
The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver diseaseZobair M Younossi, Saleh A AlQahtani, Jesús Funuyet-Salas, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 3, 2021
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in TaiwanChi-Yi Chen, Chung-Feng Huang, Pin-Nan Cheng, et al.
Metabolism: Clinical and Experimental|September 13, 2024
The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensusXu-Fen Zeng, Krista A Varady, Xiang-Dong Wang, et al.
Clinical and Molecular Hepatology|January 9, 2024
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry programMing-Ying Lu, Chung-Feng Huang, Chao-Hung Hung, et al.
Hepatology International|February 27, 2025
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver diseaseMohammed Eslam, Jian-Gao Fan, Ming-Lung Yu, et al.
Pageof 53

Showing results (501-510 of 527) with videos related to

Sort By:
Pageof 53
Scientific Reports|December 7, 2021
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in TaiwanChung-Feng Huang, Hsing-Tao Kuo, Te-Sheng Chang, et al.
Journal of Viral Hepatitis|September 13, 2025
Impact of Concurrent Steatotic Liver Disease and Chronic Hepatitis B on Treatment Response to Nucleos(t)ide AnalogsAngela Chau, Jie Li, Dae Won Jun, et al.
Hepatology International|January 21, 2024
An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from TaiwanMing-Lung Yu, Chi-Ming Tai, Lein-Ray Mo, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 6, 2022
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in TaiwanChing-Chu Lo, Chung-Feng Huang, Pin-Nan Cheng, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 5, 2021
Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision MedicineJiyoon Park, An K Le, Tai-Chung Tseng, et al.
JHEP Reports : Innovation in Hepatology|July 18, 2024
The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver diseaseZobair M Younossi, Saleh A AlQahtani, Jesús Funuyet-Salas, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 3, 2021
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in TaiwanChi-Yi Chen, Chung-Feng Huang, Pin-Nan Cheng, et al.
Metabolism: Clinical and Experimental|September 13, 2024
The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensusXu-Fen Zeng, Krista A Varady, Xiang-Dong Wang, et al.
Clinical and Molecular Hepatology|January 9, 2024
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry programMing-Ying Lu, Chung-Feng Huang, Chao-Hung Hung, et al.
Hepatology International|February 27, 2025
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver diseaseMohammed Eslam, Jian-Gao Fan, Ming-Lung Yu, et al.
Pageof 53